Does Blue Cross Blue Shield of Arizona Cover Metformin?

How BCBSAZ Formularies Are Organized

Most BCBSAZ commercial plans use a five-tier formulary. Tier 1 contains the lowest-cost preferred generics, Tier 2 holds non-preferred generics or low-cost brands, and Tiers 3 through 5 escalate toward specialty drugs that may cost hundreds of dollars per fill. Generic metformin hydrochloride (immediate-release and extended-release) almost always lands on Tier 1.

The FDA approved the first generic metformin formulations decades ago, and today the agency lists more than 30 approved generic manufacturers in its Orange Book database, making the drug one of the most competitively priced oral medications in the United States. [1] That competitive pricing is a direct reason insurers consistently slot it into the lowest tier.

Immediate-Release vs. Extended-Release Coverage

Immediate-release metformin (taken two to three times daily with meals) and extended-release metformin (taken once or twice daily) are both covered under most BCBSAZ plans. Some plans place the ER formulation at Tier 2 rather than Tier 1 because certain ER generics carry a slightly higher wholesale acquisition cost than the IR tablets. The clinical difference between the two formulations is modest: the UKPDS 34 trial, which followed 1,704 overweight patients with newly diagnosed type 2 diabetes for a median of 10.7 years, was conducted entirely with immediate-release metformin, yet the ER form was developed specifically to reduce gastrointestinal side effects that cause some patients to stop the drug. [2]

If your plan places ER metformin at Tier 2, your prescriber can document medical necessity (gastrointestinal intolerance to the IR form) and request a formulary exception, which BCBSAZ is required to review within 72 hours for non-urgent cases under federal managed care rules.

Medicare Advantage vs. Commercial Plans

BCBSAZ administers both commercial group/individual plans and Medicare Advantage (MA) plans branded as Blue Cross Blue Shield Medicare Advantage. The MA formularies are governed separately under CMS Part D rules. CMS requires all Part D plans to cover at least two drugs in every therapeutic category, and metformin qualifies as a protected-class generic under diabetes drug categories. [3] Out-of-pocket costs for MA members in 2024 are capped differently than commercial plans: under the Inflation Reduction Act, Part D enrollees pay no more than $35 per month for covered insulin products, but that cap does not automatically extend to metformin. Metformin copays on MA plans typically run $0 to $10 per month.

What Metformin Is and Why It Is Prescribed So Widely

Metformin is a biguanide oral antihyperglycemic agent first approved by the FDA in 1994 for type 2 diabetes mellitus in adults, with the pediatric indication (age 10 and older) added shortly after. [4] Its primary mechanisms include suppressing hepatic glucose production, improving peripheral insulin sensitivity, and modestly reducing intestinal glucose absorption.

Clinical Evidence Base

The UKPDS 34 trial remains the cornerstone study. Compared with conventional diet therapy, metformin reduced any diabetes-related endpoint by 32% (P<0.0001), diabetes-related death by 42% (P<0.017), and all-cause mortality by 36% (P<0.011) in overweight patients. [2] Those reductions were achieved at doses up to 2,550 mg per day, the maximum approved dose in the U.S.

The Diabetes Prevention Program (DPP, N=3,234) showed that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% over 2.8 years compared with placebo in adults with prediabetes (impaired fasting glucose and impaired glucose tolerance). [5] The lifestyle intervention arm reduced incidence by 58%, which is why the ADA recommends lifestyle first, but the DPP data gave metformin its strongest off-label foothold for prediabetes prescribing.

The American Diabetes Association's 2024 Standards of Care state: "Metformin remains the preferred initial pharmacologic agent for the treatment of type 2 diabetes due to its efficacy, safety, tolerability, and low cost." [6] That guideline language is central to why insurers cover it without barriers.

Longevity and Off-Label Interest

Metformin has attracted attention from longevity researchers because of its activation of AMP-activated protein kinase (AMPK) and possible effects on the mTOR pathway. The TAME trial (Targeting Aging with Metformin), funded by the American Federation for Aging Research, enrolled more than 3,000 adults aged 65 to 79 years across 14 U.S. Sites to test whether metformin delays age-related chronic conditions. Full results are expected in 2025. [7]

Off-label prescribing for longevity is not typically covered by BCBSAZ without a documented ICD-10 diagnosis code. The most defensible diagnosis for coverage purposes remains type 2 diabetes (E11.x) or prediabetes (R73.09), as both are recognized by ADA guidelines as appropriate indications. [6]

Prior Authorization and Step Therapy Rules

For standard type 2 diabetes, BCBSAZ does not impose prior authorization (PA) on generic metformin. PA requirements are far more common for newer agents such as GLP-1 receptor agonists (semaglutide, tirzepatide) or SGLT-2 inhibitors (empagliflozin, dapagliflozin).

Step Therapy Considerations

Some employer-sponsored BCBSAZ plans impose step therapy protocols for newer diabetes drugs, requiring documentation that metformin was tried and either failed or was contraindicated before authorizing a GLP-1 or SGLT-2 inhibitor. Arizona state law (A.R.S. §20-3321) places limits on step therapy that may override certain plan restrictions, particularly for urgent clinical situations, though the specifics depend on whether the plan is fully insured (subject to state law) or self-funded under ERISA (governed by federal rules only).

Contraindications That Affect Coverage Logic

Metformin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, and the FDA label recommends caution when eGFR falls between 30 and 45. [4] If a patient has stage 4 or 5 chronic kidney disease (CKD), a prescriber requesting metformin coverage for another indication may face a pharmacist drug-utilization review (DUR) alert rather than a formal PA denial. In that scenario, the prescriber typically writes a brief clinical note explaining that the GFR supports use, or the plan automatically routes to an alternative agent.

How to Verify Your Specific BCBSAZ Metformin Coverage

Coverage confirmation requires checking your specific plan year's formulary because BCBSAZ negotiates contracts annually and tier placements can change January 1.

Step-by-Step Verification Process

1. Log into your member portal at bcbsaz.com and manage to "Drug Coverage" or "Formulary Search."
2. Enter "metformin" and select your plan name from the dropdown.
3. Note the tier, any quantity limits (commonly 180 tablets per 30-day supply for the 500 mg twice-daily dose), and whether a PA flag appears.
4. Cross-reference with your Summary of Benefits and Coverage (SBC), which all ACA-compliant plans must provide under the Affordable Care Act. [8]
5. Call the pharmacy benefit manager (PBM) number on the back of your card (BCBSAZ uses multiple PBMs depending on plan type, including Prime Therapeutics for many commercial lines) if the online tool shows conflicting information.

Using the Pharmacy Network to Reduce Cost Further

Even with Tier 1 coverage, some BCBSAZ members find that GoodRx or Mark Cuban's Cost Plus Drugs prices metformin below their plan copay at certain pharmacies. Federal rules do not prohibit using a discount card instead of insurance for a given fill, though using a discount card means that fill does not count toward your deductible. At Cost Plus Drugs, 60 tablets of metformin 500 mg lists for approximately $5.00 as of mid-2024, which may be below some plan copays. [9]

Metformin Dosing and Administration: What Insurers Typically Authorize

Standard formulary quantity limits align with FDA-labeled dosing ranges. BCBSAZ plans typically authorize:

• Metformin IR 500 mg or 850 mg tablets: up to 4 tablets per day (maximum 2,550 mg/day per FDA label) [4]
• Metformin ER 500 mg, 750 mg, or 1,000 mg tablets: up to 2,000 mg per day for most branded and generic versions
• Liquid metformin (Riomet): Tier 2 or Tier 3 on most plans; often requires PA or formulary exception

Quantity Limit Appeals

If your prescriber needs a higher dose (for example, 3,000 mg per day in a high-body-weight patient, which some clinical endocrinologists use off-label), a quantity limit exception request citing body weight, HbA1c, and prior response data typically resolves within five business days under BCBSAZ's standard appeal timeline. The ADA notes that doses above 2,000 mg/day add limited additional glycemic benefit for most patients, so clinical justification matters. [6]

Metformin for Prediabetes: Coverage Gaps to Know

The DPP demonstrated a 31% reduction in diabetes incidence with metformin. [5] Despite that evidence, insurance coverage for metformin prescribed solely for prediabetes (ICD-10: R73.09) is inconsistent. BCBSAZ commercial plans generally do not exclude metformin from coverage based on diagnosis code alone at the pharmacy level, meaning many patients fill the prescription without issue. The real friction point is whether the prescriber's office and the PBM flag the diagnosis code and trigger a DUR review.

The CDC's National Diabetes Prevention Program (National DPP) recommends lifestyle intervention as the primary tool, with metformin as a second option for high-risk individuals (BMI <27 with other risk factors, or age <60). [10] That CDC guidance gives prescribers a defensible clinical rationale when a plan questions prediabetes prescribing.

The HealthRX clinical team has developed a three-step framework for patients seeking BCBSAZ coverage of metformin for prediabetes or off-label longevity use:

Step 1. Obtain a confirmed fasting glucose of 100 to 125 mg/dL or HbA1c of 5.7% to 6.4% (ADA prediabetes thresholds) to establish a documented ICD-10 code of R73.09. [6]

Step 2. Have your prescriber send the prescription with the R73.09 diagnosis code clearly listed. Most BCBSAZ PBMs process the fill at Tier 1 without additional review.

Step 3. If a PA is triggered, submit the DPP trial data (N=3,234, 31% risk reduction) [5] alongside the ADA's recommendation that metformin be considered for high-risk prediabetes patients under age 60 or with BMI above 35.

Metformin and GLP-1 Combination Therapy: Coverage Sequencing

Many BCBSAZ members ask whether they can be on both metformin and a GLP-1 receptor agonist simultaneously. The answer is yes, clinically. The ADA's 2024 Standards of Care support combination therapy when metformin alone does not achieve the HbA1c target, or when a patient has established cardiovascular disease, heart failure, or CKD that makes an SGLT-2 inhibitor or GLP-1 agent cardioprotectively indicated. [6]

How BCBSAZ Handles Combination Coverage

Metformin itself requires no PA under most BCBSAZ plans regardless of what other agents are on the regimen. The GLP-1 agent (semaglutide, dulaglutide, tirzepatide, liraglutide) will carry its own PA requirements, which typically include:

• Documented type 2 diabetes diagnosis (E11.x)
• HbA1c at or above 7.0% to 8.0% (threshold varies by plan year)
• Trial of metformin for a minimum of 90 days unless contraindicated
• BMI documentation for weight-management indications

The SUSTAIN-6 trial (N=3,297, 104 weeks) showed semaglutide 0.5 mg and 1.0 mg reduced major adverse cardiovascular events (MACE) by 26% vs. Placebo (P<0.001 for non-inferiority; P=0.02 for superiority). [11] That cardiovascular outcome data is one reason BCBSAZ plans may approve a GLP-1 agent alongside metformin without requiring metformin failure in patients with established cardiovascular disease.

Avoiding Step Therapy Delays

If a fully insured BCBSAZ plan requires metformin as a step before a GLP-1 agent and the patient has a contraindication (eGFR <30, lactic acidosis history, or severe GI intolerance), Arizona A.R.S. §20-3321 allows the prescriber to request a step therapy override, which the plan must respond to within 72 hours. The ERISA carve-out applies to self-funded employer plans, where federal law governs and state step therapy protections do not apply automatically.

Cost Without Insurance and Why It Matters for BCBSAZ Members

Understanding the cash price helps members decide whether to use insurance or a discount program for any given fill.

Metformin IR 500 mg, 60 tablets: approximately $4 to $10 at major retail pharmacies (Walmart, Costco, Kroger) using GoodRx or generic discount programs. [9] Metformin ER 500 mg, 60 tablets: approximately $10 to $30 depending on manufacturer and pharmacy.

For BCBSAZ members on a high-deductible health plan (HDHP) who have not yet met their deductible, the cash price plus a discount card can be lower than the plan's in-network negotiated rate before deductible satisfaction. Using a discount card for that fill does not jeopardize coverage eligibility, but it means the amount paid does not count toward the annual deductible or out-of-pocket maximum.

Side Effects, Monitoring, and What Insurers May Require

Metformin's most common adverse effects are gastrointestinal: nausea, diarrhea, and abdominal discomfort, which affect up to 30% of initiating patients but resolve in most cases within four to six weeks. [12] Starting at 500 mg once daily with the evening meal and titrating by 500 mg per week reduces GI burden significantly.

Vitamin B12 Depletion

Long-term metformin use (generally beyond two to three years) is associated with vitamin B12 malabsorption. A cross-sectional analysis of the NHANES dataset found that metformin users had a 19% higher prevalence of B12 deficiency than non-users (P<0.001). [13] The ADA recommends periodic B12 monitoring in long-term metformin users, particularly those on doses above 1,500 mg per day. [6] BCBSAZ plans typically cover a serum B12 lab test under the diagnostic lab benefit, though copay or coinsurance applies depending on plan design.

Lactic Acidosis Risk

Lactic acidosis is rare (fewer than 10 cases per 100,000 patient-years in population studies) but serious. [12] The risk rises meaningfully only when metformin is used in the presence of significant renal impairment, hepatic failure, or acute illness causing tissue hypoperfusion. Routine monitoring of renal function (at least annually, or every three to six months when eGFR is 30 to 60) is supported by the FDA label [4] and is covered under most BCBSAZ preventive and diagnostic benefits.

Key Takeaways for BCBSAZ Members Seeking Metformin Coverage

Generic metformin sits at Tier 1 on nearly all BCBSAZ commercial and Medicare Advantage formularies with copays between $0 and $15 per 30-day supply. No prior authorization is required for a standard type 2 diabetes diagnosis. Prediabetes coverage is generally available but depends on the prescriber using the correct ICD-10 code (R73.09) and, in some cases, submitting brief clinical documentation. Off-label use for longevity without a metabolic diagnosis code is unlikely to be covered without appeal.

Verify coverage annually each January, confirm your plan's quantity limits, and ask your prescriber to include the diagnosis code on every prescription to avoid pharmacy-level DUR delays. If a GLP-1 agent is also being requested, confirm with your prescriber that metformin documentation (or a contraindication note) is in the chart before the GLP-1 PA is submitted.

The ADA 2024 Standards of Care recommend beginning metformin at 500 mg once or twice daily with meals and titrating to a target of 1,500 to 2,000 mg per day over four to eight weeks, adjusting for tolerability and renal function. [6]